Alzheimer’s Disease International (ADI) published a comprehensive report on September 21 indicating that global clinical research targeting dementia has entered an expansion phase after years of high-profile trial failures. The registry tracks 158 potential therapeutic agents undergoing 192 clinical trials worldwide, reflecting a broader diversification of biological targets and drug classes beyond traditional avenues.
Global Alzheimer’s Disease Research Reaches Milestone With 158 Candidate Treatments in Clinical Trials
Eight major Phase 3 trials are expected to deliver critical efficacy and safety data throughout 2026. Phase 3 evaluations represent advanced clinical development, testing candidates in larger patient cohorts to confirm therapeutic benefit and safety profiles prior to regulatory submission. Alongside traditional proprietary compounds, researchers are actively investigating drug repurposing strategies—evaluating molecules originally developed for entirely different medical conditions against neurodegenerative pathways.
European Union Approvals Face Access Hurdles in Sweden
While therapeutic development accelerates globally, market access varies significantly by jurisdiction. Two monoclonal antibody treatments targeting amyloid-beta plaque accumulation—lecanemab, marketed as Leqembi, and donanemab, marketed as Kisunla—have secured European Union marketing authorizations for adult patients diagnosed with early-stage Alzheimer’s disease.
Despite the centralized European approval, commercial availability remains restricted at the national level. In Sweden, the regional drug evaluation body NT-rådet recommended that healthcare regions refrain from adopting Leqembi. The agency cited a narrow and uncertain clinical benefit relative to the overall cost, alongside significant resource demands. The administration protocol requires intravenous infusion delivery coupled with serial magnetic resonance imaging (MRI) monitoring to manage risks of amyloid-related imaging abnormalities, which can include cerebral edema and microhemorrhages.
For Kisunla, the national health economic assessment concluded in September via the Dental and Pharmaceutical Benefits Agency (TLV). The dossier now sits with NT-rådet to determine its future implementation framework within Swedish public healthcare infrastructure.
Diagnostic Advances Highlight the Need for Early Detection
Because newly authorized disease-modifying therapies are explicitly indicated for individuals in the earliest stages of cognitive decline, timely and accurate diagnosis carries heightened clinical importance. Diagnostic pathways are shifting rapidly through the introduction of blood-based biomarker assays capable of detecting pathological changes associated with amyloid and tau proteins.
Despite these technical capabilities, Swedish medical authorities have cautioned against direct-to-consumer commercial blood tests marketed independently to individuals without symptoms. Clinicians emphasize that biomarker results require rigorous interpretation within a comprehensive medical evaluation.
At the same time, public healthcare systems face structural challenges meeting current diagnostic demands. Many Swedish patients experience wait times exceeding the statutory 90-day care guarantee for a formal dementia diagnosis. The integration of disease-modifying therapies requires memory clinics to expand diagnostic capacity, streamline specialist evaluations, and manage ongoing safety monitoring protocols for patients receiving complex biological treatments.
Keep reading